DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
TreatmentTrends: Hepatitis C | Treatment Algorithms | Claims Data Analysis | US | 2014
Hepatitis C virus (HCV) chronic infection is a leading cause of advanced liver disease and hepatocellular carcinoma and a common indication for liver transplantation. The FDA’s approval of Gilead…
Hepatitis C Virus (How Will All-Oral, Interferon-Free Antiviral Regimens Influence Physician and Payer Attitudes Toward Treatment and Reimbursement in the Cost-Constrained EU5?) | Physician & Payer Forum | EU5 | 2014
In January 2014, the European Medicines Agency granted marketing authorization to the first nucleotide polymerase inhibitor, sofosbuvir (Gilead’s Sovaldi), for the treatment of hepatitis C virus…
Oncology (Securing Favorable Reimbursement Status in the EU5 Oncology Markets: Evolving Physician and Payer Perspectives on Biomarker-Driven Prescribing in Oncology) | Physician & Payer Forum | EU5 | 2014
As oncology increasingly moves toward personalized approaches to therapy, the use of predictive biomarkers will become more important. A plethora of biomarker-driven brands are already available…
Major Depressive Disorder | Treatment Algorithms | Claims Data Analysis | US | 2014
For the first-line treatment of major depressive disorder (MDD), physicians most commonly prescribe a selective serotonin reuptake inhibitor (SSRI), serotonin/norepinephrine reuptake inhibitor (…
Psoriasis (How Will the Launches of Efficacious Biologics and Novel Oral Agents Affect Psoriasis Treatment and Reimbursement? Insights from U.S. Physicians and Payers) | US | 2014
Psoriasis is a chronic inflammatory skin disorder that is managed with systemic therapies for moderate to severe patients who fail first-line topical therapies and/or phototherapy. Dermatologists…
Granulocyte Colony-Stimulating Factors and Monoclonal Antibodies in Oncology (Physician Perspectives) | Biosimilars Advisory Service | US/Eu5/Japan | 2014
European oncologists have had high exposure to biosimilars compared with other European specialists owing to the availability of epoetin alfa and filgrastim biosimilars. Although no biosimilars are…
